158 results on '"Kanis, J."'
Search Results
2. The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture
3. Updated fracture incidence rates for the Italian version of FRAX®
4. European guidance for the diagnosis and management of osteoporosis in postmenopausal women
5. A global representation of vitamin D status in healthy populations
6. Treatment failure in osteoporosis
7. Burden of postmenopausal osteoporosis in Germany: estimations from a disease model
8. An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis
9. Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model
10. Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland
11. Management of Glucocorticoid-Induced Osteoporosis
12. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study
13. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis
14. A systematic review of hip fracture incidence and probability of fracture worldwide
15. FRAX® probabilities and risk of major osteoporotic fracture in France
16. Frailty and sarcopenia: definitions and outcome parameters
17. Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper
18. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008
19. Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden
20. A comparative study of using non-hip bone density inputs with FRAX®
21. Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures
22. Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study
23. A comparison of case-finding strategies in the UK for the management of hip fractures
24. Pitfalls in the external validation of FRAX
25. Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)
26. A reappraisal of generic bisphosphonates in osteoporosis
27. Fracture risk assessment without bone density measurement in routine clinical practice
28. High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice
29. Towards a diagnostic and therapeutic consensus in male osteoporosis
30. Partial adherence: a new perspective on health economic assessment in osteoporosis
31. Interpretation and use of FRAX in clinical practice
32. Evaluation of FRAX to characterise fracture risk in Poland
33. Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security
34. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®
35. Low bone mineral density is associated with increased mortality in elderly men: MrOS Sweden
36. Secular trends in the incidence of hip and other osteoporotic fractures
37. Development and validation of a disease model for postmenopausal osteoporosis
38. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective
39. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos
40. Guidance for the adjustment of FRAX according to the dose of glucocorticoids
41. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
42. Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment
43. Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement
44. Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance
45. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
46. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report
47. A FRAX® model for the assessment of fracture probability in Belgium
48. Development and use of FRAX® in osteoporosis
49. The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)
50. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.